Once you’ve engineered your microorganism to produce your billion-dollar molecule, how are you going to scale up production?

In 2020, A16Z’s Vijay Pande and Judy Savitskay wrote a paper called, The Biggest Open Opportunity in Synthetic Biology, listing out the need for novel bio-manufacturing platforms.

Last week I mentioned, I've been obsessing over generic drug manufacturing.

This isn't an out-of-the-blue Karl Schmieder obsession. I've worked on communications projects for biopharma manufacturers and, for about a decade, have written about quality control issues associated with foreign manufacturers.